The FDA gave Rock­et Phar­ma­ceu­ti­cals the green light to re­sume a clin­i­cal tri­al of its gene ther­a­py for Danon dis­ease, a rare ge­net­ic dis­or­der that af­fects mul­ti­ple or­gans, in­clud­ing the heart.

Rock­et is now restart­ing its study with both a low­er dose of the gene ther­a­py and changes to its im­mune sup­pres­sion reg­i­men. Its stock RCKT was up about 23% af­ter the news was an­nounced.

The FDA put the pro­gram on hold in May af­ter a pa­tient in the study died. That pa­tient had re­ceived a new im­mune sup­pres­sion drug, which Rock­et is no longer us­ing. The FDA lift­ed the hold in less than three months, Rock­et not­ed its re­lease.

The best things come in threes.

Over the past two weeks, Jazz Phar­ma­ceu­ti­cals wel­comed a new CEO, re­ceived ap­proval for its brain tu­mor treat­ment, and has now inked a deal for the fu­ture of its epilep­sy pipeline.

The Dublin-based drug­mak­er is part­ner­ing with San­iona on its pre­clin­i­cal epilep­sy pro­gram. It's pay­ing $42.5 mil­lion up­front to the Copen­hagen-based biotech for the ex­clu­sive glob­al li­cense to a pre­clin­i­cal drug can­di­date called SAN2355.

San­iona could al­so re­ceive an­oth­er $192.5 mil­lion in de­vel­op­ment and reg­u­la­to­ry biobucks and up to $800 mil­lion if cer­tain com­mer­cial achieve­ments are reached. Roy­al­ties range from mid-sin­gle to low-dou­ble dig­its.

With its new part­ner, Jazz hopes to go up against Bio­haven and oth­er biotechs work­ing in the Kv7.2/7.3 space.

San­iona’s stock price rose 34% on Wednes­day morn­ing on the Stock­holm stock ex­change.

XO­MA Roy­al­ty is buy­ing Mur­al On­col­o­gy for $2.03 per share, the com­pa­nies said Wednes­day morn­ing.

It's the third ac­qui­si­tion this month for XO­MA, fol­low­ing deals for vac­cine de­vel­op­er Hill­e­Vax and T cell en­gager biotech La­va Ther­a­peu­tics, both of which were dis­closed Aug. 4. It al­so ac­quired Turn­stone Bi­o­log­ics in June.

Mur­al’s stock price MU­RA was up 15% af­ter the mar­kets opened on Wednes­day, hov­er­ing around $2.08. Mur­al CEO Car­o­line Loew said in a state­ment that the deal was the re­sult of a “thor­ough and wide-rang­ing strate­gic re­view process.”

Four months ago, the Alk­er­mes spin­out end­ed clin­i­cal de­vel­op­ment of its IL-2 drug and laid off most of its staffers. It then joined the num­ber of biotech com­pa­nies trad­ing be­low cash, mean­ing its en­ter­prise val­ue (EV) was worth less than cash on hand.

Catal­ent is re­duc­ing its head­count by 350 staffers at its gene ther­a­py fa­cil­i­ty in Bal­ti­more over an “un­ex­pect­ed shift in de­mand from a large cus­tomer,” a spokesper­son told End­points News in an email.

The spokesper­son de­clined to name the client, but one of its high-pro­file cus­tomers at that site is Sarep­ta Ther­a­peu­tics. The gene ther­a­py com­pa­ny has had a tu­mul­tuous sev­er­al weeks due to a de­cline in de­mand for Ele­v­idys, dis­clo­sures of pa­tient deaths, and back-and-forth with the FDA on halt­ing ship­ments of the ther­a­py.

“Our gene ther­a­py busi­ness con­tin­ues to see strong growth and we look for­ward to work­ing on be­half of cus­tomers to de­liv­er nov­el ther­a­pies for pa­tients with ge­net­ic dis­eases/dis­or­ders,” the Catal­ent spokesper­son said.